KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Restructuring Costs (2016 - 2025)

Boston Scientific's Restructuring Costs history spans 17 years, with the latest figure at $109.0 million for Q4 2025.

  • For Q4 2025, Restructuring Costs rose 1008.33% year-over-year to $109.0 million; the TTM value through Dec 2025 reached $194.0 million, changed N/A, while the annual FY2025 figure was $194.0 million, N/A changed from the prior year.
  • Restructuring Costs for Q4 2025 was $109.0 million at Boston Scientific, up from -$8.0 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $298.0 million in Q2 2021 and bottomed at -$272.0 million in Q4 2021.
  • The 5-year median for Restructuring Costs is $8.5 million (2021), against an average of $25.6 million.
  • The largest annual shift saw Restructuring Costs skyrocketed 9833.33% in 2021 before it tumbled 2875.0% in 2023.
  • A 5-year view of Restructuring Costs shows it stood at -$272.0 million in 2021, then soared by 156.99% to $155.0 million in 2022, then increased by 16.13% to $180.0 million in 2023, then crashed by 106.67% to -$12.0 million in 2024, then surged by 1008.33% to $109.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Restructuring Costs are $109.0 million (Q4 2025), -$8.0 million (Q3 2025), and $83.0 million (Q2 2025).